03.19.13
Natreon, Inc, and NutraGenesis, LLC has revealed that Sensoril, the highest selling patented extract of Ashwagandha sold in North America, is the subject of five new human clinical trials. The studies are wide ranging in their assessment of the comprehensive health benefits of Sensoril. All five studies were randomized, double-blind, placebo-controlled trials.
The first study was conducted by researchers at the University of Pittsburgh and assessed Sensoril’s ability to enhance memory and mental cognition in a clinical setting with patients experiencing short term memory and focus issues.
The second double-blind, placebo controlled study was conducted in a multi-center clinical setting and evaluated Sensoril in the treatment of Generalized Anxiety Disorder (GAD). Generalized Anxiety Disorder affects approximately 6.8 million American adults with twice as many women being affected as men. Its symptoms include excessive worrying and the ability to relax.
An additional study investigated the effects of Sensoril on endothelial function, both when taken alone and in combination with Capros, a patented Indian Gooseberry extract. Subjects in this study were evaluated for lipid profile, inflammation (CRP reduction), glutathione increase, nitric oxide increase and blood sugar balance. The positive control in the study was a popular statin drug that has recently gone generic.
The final two studies assessed cardiovascular changes in healthy subjects under cold stress and mental stress conditions.
“We are delighted with the results of these five studies, which will be published soon, and we look forward to sharing them in the near future with our customers and the industry”, says Dr. Sanni Raju, CEO and chairman of the board of Natreon, Inc. “Our commitment to building the research and intellectual property platform for Sensoril on behalf of our customers and partners has and always will be our first priority”. Dr. Raju added, “Natreon’s intellectual property around Ashwagandha is extensive, involving several U.S. and international patents which cover extracts produced from root only with a 3% minimum withanolide content and higher, and extracts produced from root and leaf with a minimum 8% withanolide content and higher. We at Natreon take our investment into the intellectual property and scientific research for our ingredients very seriously and we actively enforce our patent rights.”
Suzanne McNeary, president of NutraGenesis, LLC, the exclusive licensee for Sensoril in North America, added, “the results of these new studies further solidify Sensoril’s superiority in the Ashwagandha marketplace. As the most concentrated, multi-patented, truly full-spectrum Ashwagandha extract with over a decade of safe and efficacious use in the industry, it’s the reason that Sensoril is the number one choice in Ashwagandha extracts of fine dietary supplement brands around the world”.
For further information: www.natreoninc.com and www.nutragenesis.com
The first study was conducted by researchers at the University of Pittsburgh and assessed Sensoril’s ability to enhance memory and mental cognition in a clinical setting with patients experiencing short term memory and focus issues.
The second double-blind, placebo controlled study was conducted in a multi-center clinical setting and evaluated Sensoril in the treatment of Generalized Anxiety Disorder (GAD). Generalized Anxiety Disorder affects approximately 6.8 million American adults with twice as many women being affected as men. Its symptoms include excessive worrying and the ability to relax.
An additional study investigated the effects of Sensoril on endothelial function, both when taken alone and in combination with Capros, a patented Indian Gooseberry extract. Subjects in this study were evaluated for lipid profile, inflammation (CRP reduction), glutathione increase, nitric oxide increase and blood sugar balance. The positive control in the study was a popular statin drug that has recently gone generic.
The final two studies assessed cardiovascular changes in healthy subjects under cold stress and mental stress conditions.
“We are delighted with the results of these five studies, which will be published soon, and we look forward to sharing them in the near future with our customers and the industry”, says Dr. Sanni Raju, CEO and chairman of the board of Natreon, Inc. “Our commitment to building the research and intellectual property platform for Sensoril on behalf of our customers and partners has and always will be our first priority”. Dr. Raju added, “Natreon’s intellectual property around Ashwagandha is extensive, involving several U.S. and international patents which cover extracts produced from root only with a 3% minimum withanolide content and higher, and extracts produced from root and leaf with a minimum 8% withanolide content and higher. We at Natreon take our investment into the intellectual property and scientific research for our ingredients very seriously and we actively enforce our patent rights.”
Suzanne McNeary, president of NutraGenesis, LLC, the exclusive licensee for Sensoril in North America, added, “the results of these new studies further solidify Sensoril’s superiority in the Ashwagandha marketplace. As the most concentrated, multi-patented, truly full-spectrum Ashwagandha extract with over a decade of safe and efficacious use in the industry, it’s the reason that Sensoril is the number one choice in Ashwagandha extracts of fine dietary supplement brands around the world”.
For further information: www.natreoninc.com and www.nutragenesis.com
